ASM Microbe 2022

Sarah Y. Park, MD¹, Asim A. Ahmed, MD¹, Eliza J. Chang¹, T. Matthew Hill, PhD¹, Kevin Messacar, MD², Nathan Ledeboer, PhD³, and Frederick S. Nolte, PhD¹ 

¹Karius, Redwood City, CA, ²University of Colorado, Children’s Hospital Colorado, Aurora, CO, ³Medical College of Wisconsin, Milwaukee, WI.

This study reports on the largest testing cohort of patients in which plasma mcfDNA has been identified and quantified. The Karius Test non-invasively detected a wide variety of pathogens, including common, rare, and difficult to detect pathogens in a clinically relevant time frame. The most frequent medical conditions included fever, pneumonia, sepsis, and immunocompromised states.

David M. Berman, DO¹, Kevin Loh¹, Aparna Arun, MD¹, Sarah Y. Park, MD¹, Ricardo Castillo-Galvan, MD¹, John Hammer, MD¹, Matt Smollin, PharmD¹, Frederick Nolte, PhD¹, Nick Degner, MD¹, Ann T. MacIntyre, DO¹, LauraLe Dyner, MD¹, Asim A. Ahmed, MD¹

¹Karius, Redwood City, CA

Non-H. pylori Helicobacter (NHPH) infections cause systemic disease in immunocompromised patients. NHPH are fastidious microorganisms, rarely detected by culture or NAAT in clinical labs. There is a diagnostic advantage of using the Karius Test to rapidly identify NHPH in immunocompromised hosts to the species level, allowing providers to select the most appropriate antimicrobial therapy. The Karius Test can also potentially be used for serial monitoring of NHPH infections.